Boom Capital Ventures

Olio Labs is a biotechnology company focused on developing combination therapeutics that leverage artificial intelligence to enhance treatment efficacy and reduce side effects. By employing automated discovery methods, the company analyzes protein interactions in the body, allowing for a more comprehensive approach to therapeutic design. Unlike traditional methods that typically target a limited number of proteins, Olio Labs' innovative strategy aims to create effective treatment solutions that consider a wider range of interacting proteins, ultimately improving patient outcomes.

Bioptimus develops a universal AI foundation model that connects biological data across different scales, from molecules to entire organisms. This enables clients to derive actionable insights and accelerate biomedical innovation.

Nabla Bio is a biotechnology company that uses artificial intelligence and lab technologies to rationally design novel proteins for drug development. They aim to create medicines and improve nutrition by engineering proteins with enhanced qualities.

BioLoomics is a biotechnology company that specializes in improving drug discovery and delivery. Founded in 2019, it offers drug screening services using biosensors to analyze drug action and toxicity in live cells. The company also develops tools for enhancing drug discovery efficiency and engineers proteins and cells for drug effect sensing with imaging technology.

Sonera Magnetics is engaged in developing advanced technology for high-performance, non-invasive brain-computer interfaces, aiming to enhance access to brain diagnostics. The company has created a magnetometer capable of measuring weak magnetic fields produced by brain activity, utilizing acoustically-driven ferromagnetic resonance. This technology operates at room temperature and in compact, portable formats, achieving sensitivity comparable to leading diagnostic tools that use superconducting sensors. Sonera Magnetics' systems are designed to facilitate the diagnosis and treatment of neurological disorders, such as epilepsy and dementia, by providing reliable brain imaging capabilities. Founded in 2018 in Berkeley, California, by Nishita Deka, Dominic Labanowski, and Sayeef Salahuddin, the company seeks to offer a practical and cost-effective solution for brain-computer interfacing.

Harmonic Discovery is a pharmaceutical company developing a kinase inhibitor drug platform to overcome cancer resistance. The platform blends biological screening, medicinal chemistry, and computational chemistry with structural modeling and machine learning to predict resistance mutations and optimize the design of small molecules that sustain target engagement while minimizing off-target effects, enabling more effective cancer treatment.

Monod Bio is a life sciences company developing biosensors for detecting proteins, toxins, antibodies and other molecules. Its biosensor platform combines binding, transduction, and amplification in one step to detect a wide range of target molecules. The company leverages computational protein engineering to create modular bio-sensing nano switches that enable rapid, sensitive, and inexpensive analytical assays. Monod Bio was founded in 2021 and is headquartered in Seattle, Washington.

Endpoint Health, Inc. is a precision immunology company focused on researching and developing therapies that enhance outcomes for patients with critical and immune-driven illnesses, including sepsis, acute respiratory distress syndrome, and COVID-19. Founded in 2018 and headquartered in Palo Alto, California, with additional offices in Detroit, Livonia, and Chicago, the company aims to overcome the limitations of traditional drug development by creating precision therapies tailored to individual patient needs. Utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health identifies and matches high-potential therapies to patients most likely to benefit, ensuring personalized treatment that significantly improves health outcomes. The company is committed to delivering innovative solutions that address the complexities of autoimmune and inflammatory conditions.

Founded in 2019, Synthesis AI is a San Francisco-based company specializing in computer vision. It offers a data generation platform that leverages synthetic data technology to enhance AI capabilities and enable more cost-effective model building.

Diligent Robotics develops hospital service robots and related AI software to assist clinical and nursing staff with logistical tasks, enabling more time for direct patient care. Its flagship robot, Moxi, operates in hospital environments to handle routine duties and collaborate with humans, supported by AI-based software that enables safe interaction and adaptation to human workflows. Founded in 2017 and based in Austin, Texas, the company seeks to improve patient satisfaction, quality of care, and safety by augmenting healthcare teams with robotic assistance.

Fauna Bio develops a cross-mammal drug discovery platform that leverages biology from hibernating and other non-model animals to identify mechanisms that protect against injury and disease. By integrating genomics, transcriptomics, metabolomics, and proteomics across hundreds of species, the company identifies novel drug targets and advances therapeutics for conditions such as heart attack, stroke, neurodegenerative diseases, and other serious human illnesses. Founded by scientists in 2018, it is based in San Francisco. The approach aims to translate natural protective biology into preclinical and early clinical testing to enable recovery from emergency medical conditions.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Orchid is a reproductive technology startup founded in 2019 and headquartered in San Francisco, California. The company specializes in detecting rare genetic disorders through its preconception system, which analyzes the genomes of both partners to assess their genetic predispositions to various common diseases, such as heart disease, Alzheimer’s disease, and breast cancer. Orchid develops its results in collaboration with leading experts in reproductive medicine and genetics, ensuring high accuracy. The company offers a "Couple Report," which utilizes an at-home saliva test to evaluate each individual’s genetic profile and predict potential genetic risks for future children. In cases of elevated risk, Orchid provides actionable insights to assist couples in monitoring health markers, adjusting their diet, or considering procedures like in vitro fertilization.

Founded in 2019, Synthesis AI is a San Francisco-based company specializing in computer vision. It offers a data generation platform that leverages synthetic data technology to enhance AI capabilities and enable more cost-effective model building.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Diligent Robotics develops hospital service robots and related AI software to assist clinical and nursing staff with logistical tasks, enabling more time for direct patient care. Its flagship robot, Moxi, operates in hospital environments to handle routine duties and collaborate with humans, supported by AI-based software that enables safe interaction and adaptation to human workflows. Founded in 2017 and based in Austin, Texas, the company seeks to improve patient satisfaction, quality of care, and safety by augmenting healthcare teams with robotic assistance.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Fauna Bio develops a cross-mammal drug discovery platform that leverages biology from hibernating and other non-model animals to identify mechanisms that protect against injury and disease. By integrating genomics, transcriptomics, metabolomics, and proteomics across hundreds of species, the company identifies novel drug targets and advances therapeutics for conditions such as heart attack, stroke, neurodegenerative diseases, and other serious human illnesses. Founded by scientists in 2018, it is based in San Francisco. The approach aims to translate natural protective biology into preclinical and early clinical testing to enable recovery from emergency medical conditions.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Diligent Robotics develops hospital service robots and related AI software to assist clinical and nursing staff with logistical tasks, enabling more time for direct patient care. Its flagship robot, Moxi, operates in hospital environments to handle routine duties and collaborate with humans, supported by AI-based software that enables safe interaction and adaptation to human workflows. Founded in 2017 and based in Austin, Texas, the company seeks to improve patient satisfaction, quality of care, and safety by augmenting healthcare teams with robotic assistance.